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Fracture nonunions develop in 10%–20% of patients with fractures, resulting in prolonged disability. Current data suggest
that bone union during fracture repair is achieved via proliferation and differentiation of skeletal progenitors within periosteal
and soft tissues surrounding bone, while bone marrow stromal/stem cells (BMSCs) and other skeletal progenitors may also
contribute. The NOTCH signaling pathway is a critical maintenance factor for BMSCs during skeletal development, although
the precise role for NOTCH and the requisite nature of BMSCs following fracture is unknown. Here, we evaluated whether
NOTCH and/or BMSCs are required for fracture repair by performing nonstabilized and stabilized fractures on NOTCHdeficient mice with targeted deletion of RBPjk in skeletal progenitors, maturing osteoblasts, and committed chondrocytes.
We determined that removal of NOTCH signaling in BMSCs and subsequent depletion of this population result in fracture
nonunion, as the fracture repair process was normal in animals harboring either osteoblast- or chondrocyte-specific deletion
of RBPjk. Together, this work provides a genetic model of a fracture nonunion and demonstrates the requirement for NOTCH
and BMSCs in fracture repair, irrespective of fracture stability and vascularity.

Introduction

Although most fractures progress to union, 10% to 20% result in
nonunions and are often associated with morbidity, prolonged
hospitalization, and increased expenses (1–3). Risk factors for
fracture nonunion can include malnutrition, infection, metabolic
disease, poor vascularization or vascular disease, fracture comminution, and most commonly, inappropriate fixation or stabilization at the fracture site (4). However, there remain questions as to
whether systemic factors or impaired cellular function may play a
role in the pathogenesis of fracture nonunion, particularly in cases
that do not heal after appropriate surgical intervention. A reduced
pool of human bone marrow stromal/stem cells (BMSCs) correlates with altered bone repair in patients with fracture nonunions
(5, 6). The administration of BMSCs has shown promise in treating
patients with fracture nonunions in some settings (7–12). Interestingly, recent studies using reporter-tagged BMSCs have demonstrated that transplanted BMSCs specifically localize within the
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fracture gap and intramedullary or internal calluses rather than
within the external callus tissues mostly derived from the periosteum and surrounding soft tissue, suggesting a localized and specific role for BMSCs in fracture repair (13, 14). While the importance of BMSC-associated osteogenesis during development has
been established, the functional role and importance of BMSCs in
fracture healing remain to be determined.
Through the use of mouse genetic studies, we and others have
demonstrated that loss of NOTCH signaling in skeletal progenitors leads to an early increase in bone mass, depletion of the BMSC
pool, and subsequent age-related bone loss (15, 16). The NOTCH
signaling pathway is a known regulator of various stem cell populations that signals via single-pass transmembrane ligands (JAG1/2
and DLL1/3/4) and receptors (NOTCH1/4), culminating in the
activation of a transcriptional complex composed of the NOTCH
intracellular domain (NICD), the mastermind-like transcriptional
coactivator (MAML), and the central regulator known as recombination binding protein for immunoglobulin kappa J region (RBPjκ)
(17). Although NOTCH signaling is critical for maintaining BMSCs
during skeletal development (15, 16), little evidence exists for a particular role for NOTCH signaling during fracture repair. Here, we
set out to test the hypothesis that NOTCH signaling in skeletal progenitors serves to preserve the numbers and maintain the progenitor status of BMSC populations that are critical for normal fracture
repair and unification, while NOTCH signaling within more committed skeletal lineages may be largely dispensable.
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Figure 1. Loss of NOTCH signaling in MSCs results in fracture nonunion. (A) A real-time radiographic comparison of 2 representative nonstabilized tibia
fractures from WT and RBPjκPrx1 mutant mice at 0, 14, 28, and 42 dpf revealed persistent fracture lines (yellow arrows) at 42 dpf, suggesting an established
fracture nonunion in RBPjκPrx1 mutants. n = 12 mice per genotype per time point. (B) μCT analyses of 14-, 28-, and 42-day-old WT and RBPjκPrx1 mutant
fractures revealed substantial periosteal external callus formation by 14 dpf and beyond, but apparent radiolucent space (yellow arrows) between broken
cortices at 42 dpf in RBPjκPrx1 mutants. n = 7 mice per genotype per time point. (C) Reconstruction of μCT data reflected the normal and robust periosteal
response in RBPjκPrx1 mutants; however, the new bone remodeling was delayed in these animals. n = 7 mice per genotype per time point. *P < 0.05 compared with WT by 2-way ANOVA followed by Dunnett’s post hoc test. Results are expressed as mean ± SD.

Results

Loss of NOTCH signaling in skeletal progenitors results in fracture
nonunion. To examine the role of NOTCH signaling during fracture repair, we generated a loss-of-function (LOF) mouse model
in which floxed alleles for the transcriptional NOTCH effector
RBPjκ were conditionally deleted in skeletal progenitors. Western blot analyses confirmed that RBPjκ was efficiently deleted
in the skeletal lineages of Prx1-Cre RBPjkfl/fl (herein referred to as
RBPjκPrx1) mice at 2 months of age (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/
JCI80672DS1). To identify the cell lineages targeted by Prx1-Cre
and contribute to callus formation during fracture repair, we analyzed tibia fractures on Prx1-Cre R26RLacZ mice at 14 days post
fracture (dpf). X-gal staining on fracture calluses revealed LacZpositive cells in the periosteum, the BM of the diaphysis, and both
the external and internal cartilaginous and bony callus (Supplemental Figure 2). These data demonstrate that all skeletal-related
cells in the callus are derived from Prx1-expressing progenitors,
which largely reside in both the periosteum and BM.
To determine whether normal fracture repair requires a
NOTCH-maintained population of BMSCs, we performed nonstabilized tibia fractures on RBPjκPrx1 (largely depleted of the clonogenic fraction of BMSCs) and WT control mice at 2 months of
age. Radiographs of WT fractures demonstrated the initial signs of
external callus forming by 14 dpf, followed by the disappearance
of the cortical gap via a bridging internal and external bony callus by 28 dpf, indicating fracture unification. In contrast, RBPjκPrx1
mutant fractures showed prominent callus formation along the
periosteum extending away from the fracture line at 14 and 28 dpf;
however, no bridging callus between the cortices was observed.
Radiographic observations out to 42 dpf demonstrated a clear
nonunion of RBPjκPrx1 mutant tibiae (Figure 1A). Consistent with
radiographic data, μCT analyses on mineralized calluses of WT
fractures showed a nearly complete bridging of bony calluses by 14
dpf, followed by complete bridging at 28 dpf and beyond. RBPjκPrx1
fractures presented with a large radiolucent space between broken
1472
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cortices at 14 dpf that remained evident up to and beyond 42 dpf
(Figure 1B). Reconstruction of μCT data revealed that mineralized callus volumes in WT fractures peaked at 14 dpf and rapidly
decreased from 14 dpf to 42 dpf, suggesting continuous external
callus remodeling. Quantitatively, substantial new external callus bone formation was observed in RBPjκPrx1 mutant fractures,
reflecting relatively normal and robust periosteal and soft tissue
responses in these mutants. In contrast, bone remodeling was
likely delayed in RBPjκPrx1 mutant fractures, since callus volumes
did not show a decline until beyond 28 dpf (Figure 1C).
A fibrous hypertrophic nonunion develops in RBPjκPrx1 mutant
fractures. Histological assessments of fracture repair were performed using alcian blue/hematoxylin/orange-g (ABH/OG) staining of RBPjκPrx1 mutant and WT fracture calluses at 7, 14, 28, and
42 dpf (Figure 2A). At 7 dpf, WT and RBPjκPrx1 mutant fracture
calluses were comparable, with early signs of mesenchymal cell
recruitment, cartilage formation in the external calluses, and the
appearance of vascular tissue noted by the presence of red blood
cells (Figure 2A). By 14 dpf, further callus formation in WT fractures was observed in 3 areas, including (a) the endosteal surface
close to the fracture rim and within the intramedullary BM space,
(b) the fracture gap directly adjacent to the fractured cortices, and
(c) the periosteal surface of both proximal and distal sides of the
tibiae, where the transition from cartilaginous to bony callus was
nearly complete. By 28 dpf, the cortices in WT fractures were unified by bridging calluses in both the periosteal and intramedullary
areas. Due to bony union and new bone remodeling, WT fractures
were completely repaired, as illustrated by the restoration of the
original lamellar structure of the cortical bone by 42 dpf (Figure
2A). Alternatively at 14 dpf, RBPjκPrx1 mutants exhibited no internal
callus formation, but rather displayed a persistence of undifferentiated mesenchymal tissue within both the intramedullary space
and the fracture gap. Interestingly, relatively normal external callus formation could be visualized along the periosteal surfaces,
although the replacement of cartilage by bone was delayed, suggesting the periosteal-derived stem/progenitor cell (PSC) popu-
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Figure 2. Loss of NOTCH signaling in MSCs results in histological changes
consistent with the pathology of fracture nonunion. (A) ABH/OG-stained
callus sections from WT and RBPjκPrx1 mutants at 7, 14, 28, and 42 dpf
showed prominent external callus formation (blue dotted line area) and
persistent mesenchymal tissue (yellow dotted line area) within the internal
callus area, which was ultimately filled with mesenchymal fibrous tissue
(green arrows) in RBPjκPrx1 mutant fractures. Mesenchymal/fibrotic callus
regions are shown at high magnification in blue boxes. n = 5 mice per
genotype per time point. (B) IHC for COL3A1 on callus sections from WT and
RBPjκPrx1 mutant fractures at 14, 28, and 42 dpf confirmed the formation of
mesenchymal-like fibrous tissue in the fracture gap of RBPjκPrx1 mutants.
n = 5 mice per genotype per time point. Original magnification, ×5. Red
arrows indicate the expression of COL3A1.

lation was largely unaffected in RBPjκPrx1 mutant mice. By 28 dpf
and beyond, regions of the intramedullary space and fracture
gap mostly were filled with mesenchymal fibrous tissue (Figure
2A). To determine the fibrotic nature of the mesenchymal tissue
that developed and persisted at the fracture site, we performed
immunohistochemistry (IHC) for COL3A1 (Figure 2B). COL3A1
expression, which was minimally visualized in WT fracture sections at 14 dpf, dissipated over time, as it does during normal
fracture repair. Alternatively, COL3A1 appeared to be more pronounced over the course of healing in RBPjκPrx1 mutant fracture
sections, especially within the fracture gap and the intramedullary
mesenchymal area, confirming that a fibrous nonunion developed
in these mutant mice (Figure 2B).
We next performed quantitative assessments of tissue composition of fracture calluses to further understand fracture healing
in these mice. Consistent with histological observations, histomorphometric results revealed that the cartilage and bone areas
were significantly increased in RBPjκPrx1 mutant fractures throughout much of the fracture repair process, which was attributed to
the robust endochondral bone formation that occurred along the
periosteal surfaces as well as the delayed bone remodeling (Figure 3A). The significantly greater amount of mesenchymal tissue
observed throughout the healing process in RBPjκPrx1 mutant frac-

tures mostly appeared within the internal or intramedullary callus
area and ultimately caused the lack of any bone unification (Figure
3A). To determine the structural impact of the altered fracturehealing processes, we analyzed fractured WT and RBPjκPrx1 mutant
tibiae at 42 dpf using biomechanical torsion testing. As expected,
all biomechanical parameters, including bone strength, bone
stiffness, and bone toughness, were markedly lower in RBPjκPrx1
mutant tibiae (~7-fold lower, P ≤ 0.002) (Figure 3B). No failure
moment could be specifically detected in RBPjκPrx1 mutant tibiae,
indicating the complete absence of any rigid unifying structure
(Figure 3B). In addition, the minimal torsional stiffness possessed
by RBPjκPrx1 mutant fractured tibiae suggested soft tissue bridging
of bone fragments, resulting in a slow tearing rather than abrupt
breaking during tests (Figure 3B). The fully restored mechanical
competence in the WT group, compared with nearly undetectable
parameters in the mutant group, demonstrated not just delayed
fracture repair, but rather an actual and complete nonunion.
The fracture nonunions observed in RBPjκPrx1 mutants are likely
due to the depleted and/or defective BMSC pool, rather than altered
vascularization or osteoclast numbers. To determine whether
alterations in vascularization contribute to fracture nonunions in
RBPjκPrx1 mutants, we performed PECAM immunofluorescence
(IF) on callus sections at 14 dpf. In regions of the external callus,
we observed similar patterns of vascularization between WT and
mutant fractures. The cartilaginous tissue was avascular, and
new blood vessels invaded areas of new bone formation, indicating normal endochondral bone healing within external calluses
from both groups (Supplemental Figure 3, B and E). Within areas
of internal calluses of WT fractures, we also observed that bone
fragments were bridged by avascular cartilaginous tissue flanked
by vascular tissue (Supplemental Figure 3, A and C). Surprisingly,
abundant PECAM expression was observed across the fracture
gap containing mesenchymal-like fibrous tissue without evidence
of bone formation in RBPjκPrx1 mutants (Supplemental Figure 3, D
and F). Thus, it was unlikely that the fracture nonunions observed
in RBPjκPrx1 mutants could be attributed to a disrupted vascular network, since the tissues within the fracture gap were highly vascularized. Vascularization at all stages of fracture repair was further
evidenced by the presence of red blood cells and vascular tissues
within the intramedullary and fibrous tissue domains observed
within the ABH/OG-stained histology sections from the RBPjκPrx1
mutant fractures (Figure 2A). Additionally, tartrate resistant acid
phosphatase (TRAP) staining for osteoclasts was also assessed
to determine whether dysregulated osteoclastogenesis could be
jci.org   Volume 126   Number 4   April 2016
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Figure 3. RBPjκPrx1 mutant fractures have altered callus composition with
remarkably inferior biomechanical properties. (A) Histomorphometric
quantifications of the cartilage, bone, and mesenchymal areas (Ar.) from
ABH/OG-stained sections show robust cartilage and bone formation in
the external callus regions and the progression of fracture nonunion in
RBPjκPrx1 mutant fractures. n = 5 mice per genotype per time point. *P
< 0.05 compared with WT by 2-way ANOVA followed by Dunnett’s post
hoc test. Results are expressed as mean ± SD. (B) Biomechanical torsion
testing of WT and RBPjκPrx1 mutant fractures at 42 dpf. All biomechanical
parameters, including the maximum torque, torsional rigidity, and energy
to maximum, which represent the bone strength, bone stiffness, and
bone toughness, respectively, were markedly lower in RBPjκPrx1 mutant
repaired tibia than those in the WT controls. n = 7 mice per genotype. *P <
0.05 compared with WT by 2-tailed, unpaired Student’s t test. Results are
expressed as mean ± SD.

an underlying contributor to fracture nonunion. While the total
number of TRAP-positive cells observed throughout mutant fracture sections was greater than that in WT controls (Supplemental
Figure 4A), the percentage of bone surface covered by osteoclasts
(OC.S./B.S.) was comparable or lower (Supplemental Figure 4B).
Therefore, these data indicate that the fracture nonunions in
RBPjκPrx1 mutants are not caused by enhanced osteoclastogenesis.
Previous studies have demonstrated that loss of NOTCH
signaling in skeletal progenitors significantly enhanced trabecular bone mass in adolescent mice at the expense of depleting the
BMSC or skeletal progenitor pool (15, 16). We reasoned that the
fracture nonunion observed in RBPjκPrx1 mutants might be due to
this significant reduction in BMSCs. Since skeletal progenitors
are found in the clonogenic subset of adherent BM-associated
cells identified by CFU assays, we isolated cells from WT and
RBPjκPrx1 mutant fractures at 42 dpf and assayed for CFU-fibroblastic (CFU-F) and CFU-osteoblastic (CFU-OB) frequency in
BM-associated cells. Crystal violet staining of CFU-Fs and alkaline phosphatase (ALP) staining of CFU-OBs revealed remarkably
fewer type Ι CFU-Fs and CFU-OBs in the BM of RBPjκPrx1 mutant
fractures (Figure 4, A and B), indicating a severe diminution of
the clonogenic fraction of the BMSC pool. Interestingly, the ratio
of CFU-OB to CFU-F was significantly higher in the BMSC cultures from RBPjκPrx1 mutant fractures (Figure 4B), suggesting the
remaining clonogenic BMSCs were less “stem-like” and more
differentiated than those present in WT fractures. To determine
the direct impact of NOTCH inhibition on clonogenic subsets
of BMSCs, we performed CFU-F assays using BMSCs isolated
1474
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from 2-month-old WT C57BL6/J mice treated with either 10 μM
N-[(3,5-difluorophenyl)acetyl]-l-alanyl-2-phenyl]glycine-1,1-dimethylethyl ester (DAPT) (Calbiochem), a γ-secretase inhibitor
that inhibits all NOTCH signaling, or DMSO as a control. Crystal
violet staining of BMSC cultures with continuous NOTCH inhibition from days 3 to 17 after plating showed a dramatic reduction
in type I CFU-Fs compared with that in DMSO-treated controls
(Figure 4, C and D). Gene-expression analyses from these cultures demonstrated direct NOTCH inhibition in BMSCs via the
downregulation of the NOTCH target gene hairy and enhancer of
split 1 (Hes1) (Figure 4E). DAPT treatments subsequently resulted
in a dramatic downregulation of leptin receptor (Lepr) expression
(Figure 4E), which marks a critical subset of clonogenic BMSCs
specifically derived from the intramedullary and endocortical
BM and serves as an important skeletal progenitor source that
contributes to normal fracture repair (18). Consistent with this
reduction of skeletal progenitors or early osteogenic cells following 2 weeks of DAPT treatments, we observed a decrease in collagen type I alpha 1 (Col1a1) expression and a subsequent increase
in Alp and osteocalcin (Oc) expression, suggesting that remaining
cells were a more committed osteogenic cell population (Figure
4E). Collectively, these data argue that NOTCH signaling inhibition directly within skeletal progenitors results in a significant
effect on BMSC populations, such that they lose their progenitor
status with time and that, following fracture, RBPjκPrx1 mutants
likely form fibrous nonunions due to the depletion of BMSC populations with altered differentiation potential.
Loss of NOTCH signaling in osteoblasts or chondrocytes does
not result in fracture nonunion. Thus far, we could not rule out the
possibility that NOTCH-defective osteoblasts or chondrocytes
contribute significantly to the nonunion phenotype observed in
RBPjκPrx1 mutant fractures, since the Prx1-Cre lineage traces to
more committed osteoblast and chondrocyte populations during
fracture repair (Supplemental Figure 2). Therefore, to determine
whether loss of NOTCH signaling in osteoblasts could also lead
to fracture nonunion, we first traced the fate of Col1a1(2.3 kb)–
expressing osteoblastic cells during fracture repair by analyzing
the fracture callus of Col1a1-Cre(2.3 kb) R26RLacZ mice at 14 dpf.
X-gal staining revealed LacZ-positive cells in the cambium layer
of the periosteum, but not in the BM (Supplemental Figure 5, D
and F). Furthermore, we observed a large number of LacZ-positive cells in the external callus, in particular, in regions of hard
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Figure 4. Fracture nonunions observed in
RBPjκPrx1 mutants are likely due to the significant reduction of BMSC numbers and altered
differentiation status. (A) CFU-F assays on
BMSCs isolated from WT and RBPjκPrx1 mutant
fractures at 42 dpf. Representative images
for crystal violet staining of CFU-Fs and ALP
staining of CFU-OBs are both shown. (B)
RBPjκPrx1 mutant fractures are associated with
significantly reduced type 1 colonies (CFU-Fs)
and ALP-positive colonies (CFU-OBs), but an
increased ratio of CFU-OB to CFU-F. n = 6 mice
per genotype. *P < 0.05 compared with WT by
2-tailed, unpaired Student’s t test. Results are
expressed as mean ± SD. (C) CFU-F assays for
BMSCs isolated from WT mice at 2 months of
age and treated with either DMSO or DAPT for
14 days beginning on their third day in culture.
Representative images for crystal violet staining of CFU-Fs are shown. (D) Quantification of
DMSO- and DAPT-treated BMSC cultures show
significantly reduced type 1 colonies (CFU-Fs).
*P < 0.05 compared with DMSO control by
2-tailed, unpaired Student’s t test. Results
are expressed as mean ± SD of 4 independent
experiments. (E) Relative gene expression for
Hes1, Lepr, Col1a1, Alp, and Oc in DAPT-treated
BMSCs as compared with DMSO-treated control. *P < 0.05, compared with DMSO control
by 2-tailed, unpaired Student’s t test. Results
are expressed as mean ± SD of 3 independent
experiments.

calluses. In contrast, no LacZ-positive cells were detected within
the developing internal callus (Supplemental Figure 5, H and J).
These results indicate that Col1a1(2.3 kb)–expressing osteoblasts
in the periosteum only contribute to the formation of the external callus, but not the internal callus. We next analyzed fractures
from mice with NOTCH signaling selectively removed from
osteoblasts using the Col1a1-Cre(2.3 kb) transgenic line (Col1a1Cre(2.3 kb); RBPjkfl/fl, hereafter RBPjκCol1). Western blot analyses
confirmed that RBPjκ was efficiently deleted in osteoblasts of
RBPjκCol1 mice (Supplemental Figure 6). We then performed nonstabilized tibia fractures on RBPjκCol1 or RBPjkfl/fl (WT control)
mice. No significant differences in fracture repair between the
2 groups were revealed by any of the analyses, including radiographic, μCT, histological, and histomorphometric assessments
(Figure 5). We also detected comparable CFU-Fs and CFU-OBs
in the BM from RBPjκCol1 mutant fractures and controls at 42 dpf,
indicating that the BMSCs in RBPjκCol1 mutants were unaffected
by loss of NOTCH signaling in maturing osteoblasts (Supplemental Figure 7). These data demonstrate that RBPjκCol1 mutant mice,
in which NOTCH signaling is selectively removed in mature
osteoblasts, are capable of normal fracture repair.
To determine whether loss of NOTCH signaling in fracture
callus chondrocytes could also lead to fracture nonunion similar
to that observed in RBPjκPrx1 mutants, we performed nonstabilized
tibia fractures on tamoxifen-inducible (TM-inducible) Acan-

CreERT2 RBPjkfl/fl (hereafter RBPjκAcanTM) and WT control mice at 2
months of age. RBPjκAcanTM and WT mice received TM (1 mg/10
g body weight) via intraperitoneal injections at 3, 5, 7, and 9 dpf
to induce recombination of RBPjk floxed alleles following initiation of fracture repair during the chondrogenic or endochondral
phase. Radiographs showed the initiation of mineralized callus at 14 dpf and complete bridging and bony union in both WT
and RBPjκAcanTM mutant mice by 28 dpf (Figure 6A). IHC analyses
from WT and RBPjκAcanTM fracture calluses at 10 dpf during the
endochondral phase confirmed an extremely efficient removal
of RBPjκ specifically from within chondrocytes and not adjacent
mesenchymal/osteogenic tissue (Figure 6B). Histological analyses at both 10 and 28 dpf further confirmed the radiographic
results and demonstrated that RBPjκAcanTM mutant mice undergo
normal fracture repair processes with timely bony union (Figure
6B). Collectively, these data demonstrate that NOTCH signaling
is dispensable in the differentiated cell lineages of osteoblasts or
chondrocytes during fracture repair, while NOTCH signaling in
the earliest skeletal progenitors is absolutely required for normal
bone healing and unification.
Insufficient fracture stabilization is not required for fracture nonunion observed in RBPjκPrx1 mutants. To exclude the possibility that
fracture nonunion observed in RBPjκPrx1 mutants was promoted by
insufficient stabilization, we employed a rigidly stabilized femur
osteotomy model. Two different gap sizes (1.2 mm and 0.66 mm)
jci.org   Volume 126   Number 4   April 2016
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Figure 5. Loss of NOTCH signaling in mature
osteoblasts does not lead to fracture
nonunion. (A) A real-time radiographic
comparison of 2 representative nonstabilized tibia fractures from WT and RBPjκCol1
mutant mice at 0, 14, 28, and 42 dpf revealed
normal fracture repair in RBPjκCol1 mutants.
n = 7 mice per genotype. (B) Representative
μCT images of fracture calluses from WT and
RBPjκCol1 mutants at 42 dpf. n = 7 mice per
genotype. *P < 0.05 compared with WT by
2-tailed, unpaired Student’s t test. Results
are expressed as mean ± SD. (C) Reconstruction of μCT data revealed a similar amount of
mineralized calluses between WT and RBPjκCol1
mutants at 42 dpf. (D) ABH/OG-stained callus
sections from RBPjκCol1 mutants and controls
at 42 dpf. Original magnification, ×2.5. (E and
F) Histomorphometric analyses of ABH/OGstained callus sections indicated no significant
differences in bone and mesenchyme area
between WT and RBPjκCol1 mutant fractures.
n = 7 mice per genotype. *P < 0.05 compared
with WT by 2-tailed, unpaired Student’s t test.
Results are expressed as mean ± SD.

of osteotomy were created in femurs of RBPjκPrx1 mutants and
WT controls and stabilized with a rigid internal fixator. By 14 dpf,
radiographs revealed complete periosteal bridging in the control
mice with a 1.2-mm osteotomy. In contrast, although the osteotomy gap narrowed and obscured on radiographs, radiolucent space
could still be observed at 42 dpf in RBPjκPrx1 mutant femurs (Figure
7A). Three-dimensional reconstructed μCT images also demonstrate impaired healing and nonunion in RBPjκPrx1 mutant femurs
(Figure 7B). Quantitatively, the bony callus within the 1.2-mm
defect, representing the volume of the internal callus, was significantly lower in the RBPjκPrx1 mutants. The values of the minimum
polar moment of inertia (PMOI) (0.76 mm4) were significantly less
than those of controls (4.60 mm4), indicating a lack of bone union
and a high propensity of failure (Figure 7, C and D). Histologically, at 42 dpf, the 1.2-mm WT osteotomies exhibited complete
continuity of the cortex with mature lamellar structure and normal BM, whereas no healing was evident in RBPjκPrx1 mutants. In
place of normal healing, RBPjκPrx1 mutant osteotomies developed
a cap-like structure sealing the medullary canal. Often, one segment would have some mineralization and bone formation near
the osteotomy site, while the other was occupied by loose, fibrous
tissue (Figure 7E). IHC for COL3A1 on 42 dpf mutant osteotomy
sections further confirmed the fibrotic nature of the tissue within
the osteotomy gap (Figure 7E).
For the 0.66-mm osteotomies, autoradiographs indicated
bony bridging in the control group at 14 dpf; however, by 21 dpf,
the RBPjκPrx1 mutants still exhibited a radiolucent area at the level
1476
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of the osteotomy (Supplemental Figure 8A). μCT scanning showed
the same pattern of defective repair as observed in the autoradiographs (Supplemental Figure 8B). Histological analysis at 21 dpf
demonstrated that new mineral deposition bridged the osteotomy
gap, and islands of disorganized bone formed in the marrow space
of WT controls. Alternatively, by 21 dpf, only one side of the bone
fragments displayed bridging in RBPjκPrx1 mutants, with small
islands of mineralized trabecular bone in the intramedullary cavity. The opposing cortical bone did not show signs of healing or
callus formation (Supplemental Figure 8C), indicating that the
mutant osteotomy resulted in incomplete and inappropriate bridging. Therefore, osteotomies in RBPjκPrx1 mutants developed either
incomplete unions or nonunions, suggesting that insufficient stabilization is not required for fracture nonunion to occur, although
defect size may contribute to the healing outcome.

Discussion

NOTCH signaling is a recently established pathway critical to
skeletal development and disease in both mice (15, 16, 19–25)
and humans (26–28). Fracture-repair mechanisms are believed
to recapitulate a series of spatiotemporal cellular and signaling
events that occur during skeletal development (29, 30), suggesting
a potential involvement of NOTCH signaling. Evidence that further implicates NOTCH in the general processes of fracture repair
has recently emerged, including: (a) an upregulation of some
NOTCH components in murine callus tissues during fracture
healing (31), (b) a downregulation of NOTCH signaling specifi-
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Figure 6. Loss of NOTCH signaling in fracture callus chondrocytes does not
result in fracture nonunion. (A) A real-time radiographic comparison of 2
representative nonstabilized tibia fractures from WT and RBPjκAcanTM mutant
mice at 0, 14, and 28 dpf, revealed normal fracture repair in RBPjκAcanTM
mutants. n = 5 mice per genotype per time point. (B) IHC- and ABH/OGstained callus sections from RBPjκAcanTM mutants and controls at 10 and 28
dpf. IHC analyses for RBPjκ shows an extremely efficient removal of RBPjk
protein in RBPjκAcanTM mutant cartilage calluses. ABH/OG-stained callus sections indicate no identifiable tissue or cellular alterations in fracture repair
between WT and RBPjκAcanTM mutant fractures. n = 5 mice per genotype per
time point. Original magnification, ×20 (IHC); ×5 (ABH/OG).

cally within certain mouse skeletal progenitors during early fracture repair (32), and (c) evidence that systemic downregulation of
NOTCH signaling just prior to fracture prolongs the inflammatory
phase and alters fracture healing in mice (33). While these studies
have implicated NOTCH in the fracture-repair process, the precise
role of NOTCH within specific cell lineages remained unknown.
Our findings here provide what we believe is the first genetic evidence that NOTCH signaling removal specifically within skeletal
progenitors results in clonogenic BMSC depletion and fracture
nonunion, while NOTCH removal in maturing osteoblasts and
chondrocytes leads to no impairment in fracture healing and bone
unification (34, 35). Our use of multiple fracture modalities and
multiple gene targeting approaches has proven the requisite role
for BMSCs and NOTCH signaling within BMSCs during fracture
repair, irrespective of fracture stability and vascularization. Collectively, our work implicates both defective NOTCH signaling
and BMSCs as possible causes of the failed or inappropriate intramedullary callus formation leading to fracture nonunions.
Current dogma suggests that various skeletal progenitors are
recruited to the fracture site during bone repair, with at least 2
likely participants being BMSCs and PSCs (36, 37). Fracture callus development is known to occur at 3 specific loci: the medullary canal, the area between fractured cortices, and the extramedullary space, including the subperiosteal layer and surrounding
soft tissues (13, 14). However, the precise identity of cells contributing to callus development and their relative contribution
are not well defined. It is difficult to distinguish the precise role

of various skeletal progenitors during fracture repair, partly due
to the complex nature of the fracture-healing process, but also
due to the lack of specific progenitor markers. Thus far, studies
assessing the contribution of progenitor sources to bone healing
have largely relied on transplantation approaches (13, 14, 38–41).
In vivo lineage analyses using transplanted live bone grafts have
demonstrated that the periosteum supports endochondral ossification, while BM/endosteum supports intramembranous ossification during bone repair (40). Periosteal progenitors give rise
solely to skeletal cells specifically localized within the developing external callus (39, 40). Alternatively, reporter-tagged BM/
BMSC transplantations have demonstrated that BMSCs localize
to the fracture gap and may contribute to intramedullary or internal callus formation (13, 14). Based on these and other findings,
we speculate that skeletal progenitors derived from the periosteum and BM/endosteum contribute differently to bone healing.
While PSCs establish the external callus to provide rapid stability
to the fracture via endochondral ossification, BMSCs might act
to form the internal callus via intramembranous ossification and
contribute markedly to fracture unification. Consistent with this
hypothesis, the RBPjκPrx1 mutant fractures show a relatively normal periosteal response with robust external callus formation, but
fail to produce an internal callus and bone union, likely due to the
depletion of local BMSC populations.
Since our study utilized a constitutively expressed Prx1-Cre
transgene for the removal of NOTCH signaling in skeletal progenitors throughout skeletal development, it remains a question as to
precisely when NOTCH signaling is required within skeletal progenitors during fracture repair. It may be that NOTCH signaling is
required throughout development to maintain a functional pool of
BMSCs or skeletal progenitors that are ultimately needed following skeletal injury for appropriate and complete fracture repair, or
alternatively, NOTCH signaling may be required within BMSCs or
skeletal progenitors strictly at the time of fracture repair in order
to provide the appropriate cues directing bone unification. Parsing
these differences will require the identification of precisely which
skeletal progenitors or BMSC populations exhibit functionally
relevant NOTCH signaling and will also require the development
or use of appropriate inducible Cre-expressing transgenic mouse
lines. As we develop these tools, future studies will also examine
whether these particular NOTCH-deficient fracture nonunions
can be repaired via the transplantation of appropriate BMSC populations at appropriate cell concentrations with appropriate cell carriers or scaffolds. Further development of these tools and data will
aid in establishing the critical nature of NOTCH signaling within
specific BMSC populations that are required for normal fracture
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Figure 7. Insufficient fracture stabilization is not
absolutely required for the fracture nonunion observed
in RBPjκPrx1 mutants. (A) A real-time radiographic
comparison of 1.2-mm osteotomies in WT and RBPjκPrx1
mutants. n = 6 mice per genotype. (B) Representative
μCT images of 1.2-mm osteotomies in WT and RBPjκCol1
mutants at 42 dpf. n = 6 mice per genotype. (C and
D) Amira analyses of μCT data revealed significantly
lower bone volume and minimum PMOI in defect zone.
n = 6 mice per genotype. *P < 0.05 compared with
WT by 2-tailed, unpaired Student’s t test. Results are
expressed as mean ± SD. (E) ABH/OG staining and IHC
for COL3A1 staining on femur fracture sections (1.2-mm
osteotomy) from WT and RBPjκPrx1 mutants at 42 dpf
revealed the formation of mesenchymal-like fibrous
tissue (red arrows) in the 1.2-mm gap. n = 6 mice per
genotype. Original magnification, ×5.

repair and unification and may also provide the basis for developing cell- and/or molecular-based therapeutics aimed at challenging
skeletal repair and nonunion scenarios.
Fracture nonunions remain a challenging problem in orthopedic
surgery. Traditionally, fracture nonunions have been classified as
hypertrophic and atrophic. Hypertrophic nonunions are often associated with inadequate mechanical stabilization; therefore, immobilization alone may be sufficient for treatment. However, for atrophic
nonunions and a distressing number of cases of hypertrophic nonunions that do not heal after appropriate surgical intervention, the
causes have not been explicitly defined, and treatment options are
limited. Many nonunion animal models are currently available; however, most of these models rely on creating critical-sized segmental
defects (42, 43) or removing periosteum and BM (44, 45). These
models infrequently simulate the clinical human scenario and rarely
reflect the mechanisms for nonunions occurring in patients. In this
study, we identified a genetic mouse model for both hypertrophic
and atrophic nonunions. Specifically, we have demonstrated that
nonstabilized fractures in RBPjκprx1 mutants display (a) a persistent
fracture line, (b) no bridging callus formation between cortices, (c)
fibrosis within the fracture gap, and (d) poor biomechanical perfor1478
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mance, all of which are consistent with the clinical
assessment of human hypertrophic nonunions.
Furthermore, we observed persistence of the osteotomy gap and osseous capping of the intramedullary canal in rigidly stabilized fractures of RBPjκprx1
mice, which represent endpoint characteristics of
atrophic nonunions (2, 46). Therefore, these results
support the concept that BMSCs and potentially
NOTCH signaling are key cellular and signaling
participants in the pathogenesis of both hypertrophic and atrophic nonunion.
Fracture nonunions are sometimes considered to be avascular, although recent data suggest
that no statistically significant change in the median vessel counts of biopsies from the fracture gap
of patients with healing fractures, hypertrophic
nonunions, or atrophic nonunions can be identified (47). These findings are supported by preclinical models, which have demonstrated the highly
vascular nature of many nonunions, including
atrophic nonunions (48, 49). Our study further demonstrates that
internal callus formation can fail and fracture nonunion can occur,
even in the presence of a well-vascularized fracture. Collectively,
these data have extended our understanding of the pathophysiology of fracture nonunions and suggest that the fracture nonunions
characterized here are likely due to the biological impairment of
local skeletal progenitors at the fracture site or their depletion and
that NOTCH signaling in particular is a key regulator.
It is of note that children with Alagille syndrome caused by
JAG1 or NOTCH2 mutations have an especially high risk of lower extremity fractures, originally thought to be due to altered
bone development and metabolism brought on by improper
calcium, vitamin, and mineral regulation and/or altered osteoblast differentiation or function (50). Management of these
pathological lower extremity fractures in Alagille syndrome
patients can sometimes be challenging, with reports of recurrent fractures in some patients and poor healing outcomes and/
or postfracture deformities in others (50, 51). Therefore, it may
be important to assess BMSC status and CFU-F frequency in
the BM of Alagille patients with complicated fracture repair
scenarios and to consider BMSC or BM aspirate treatments to
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enhance fracture repair. Furthermore, based on our findings,
it may be relevant to establish the NOTCH signaling status
within BMSCs and CFU-F frequency in all cases of prolonged
fracture nonunion, especially when fractures do not heal even
after appropriate surgical intervention, as it may be that these
individuals have deficient or defective NOTCH signaling within their clonogenic populations of BMSCs.

Methods

Experimental animals. All mouse strains, including RBPjkfl/fl, Prx1Cre, and Col1a1-Cre(2.3 kb), have been described previously (52–54).
Prx1-Cre RBPjkfl/fl, Prx1-Cre R26RLacZfl/fl, Col1a1-Cre(2.3 kb) RBPjkfl/fl,
Col1a1-Cre(2.3 kb) R26RLacZfl/fl, and Acan-CreERT2 RBPjkfl/fl mice were
viable and produced in Mendelian ratios. Mice were fractured at 8 to
10 weeks of age. Acan-CreERT2 RBPjkfl/fl mice received TM (1 mg/10 g
body weight) via intraperitoneal injections on 3, 5, 7, and 9 dpf.
Fracture model. Prior to surgery, mice were anesthetized with
2.5% avertin (15 μl/g body weight) injected intraperitoneally. In the
nonstabilized tibia fracture model, after the mice were anesthetized,
an incision along the anterior side of the tibia was made. A transverse
osteotomy was unilaterally performed at the mid-shaft of the tibia
with a rotary bone saw. Fractured bones were repositioned without fixation, and the incision was closed. In the rigidly stabilized
femur-fracture model, the right femur was exposed by a direct lateral approach, and a 4-hole titanium plate was installed across the
anterolateral surface using 4 titanium screws (55) (RISystem). For
the 0.66-mm defect, a transverse osteotomy was cut through the
femoral middiaphysis using a 0.66-mm wire Gigli saw and a cutting
guide (RISystem). The 1.2-mm osteotomy was created by making 2
transverse cuts with a 0.22-mm wire Gigli saw and a cutting guide.
The wound was closed, and the bone was allowed to heal for up to
6 weeks. Following surgery, mice were kept in cages after recovery
from anesthesia, allowing free unrestricted weight bearing, and
buprenorphine was administered subcutaneously (0.1 mg/kg) to
manage pain every 6 to 12 hours, beginning at the time of sedation,
for up to 3 days following surgery. Fractures were confirmed immediately after surgery, and healing of the fractures was monitored weekly after fracture under anesthesia using a Faxitron Cabinet X-Ray
System (Faxitron X-Ray Corp.).
μCT assessment of the mineralized callus and biomechanical torsion
testing. After careful dissection, repaired tibiae and femurs from days
14, 28, and 42 were imaged using a μCT system (VivaCT 40, Scanco
Medical), with an integration time of 300 ms, a current of 145 mA, and
an energy setting of 55 kV. The threshold was chosen using 2D evaluation of several slices in the transverse anatomic plane so that mineralized callus was identified, but surrounding soft tissue was excluded.
Quantification for the volumes of the bony calluses was determined as
previously described using Scanco analysis software (56).
μCT image processing and analysis was also performed using
Amira software (Amira 5.4.5, FEI Visualization Sciences Group).
The volume of newly formed bone was measured from the 1.2-mm
region (114 slices) that corresponded with the initial osteotomy
after applying a bone mineral density threshold of 435 mg HA/cm3
to binarize the image. Additionally, the PMOI, which is correlated
with the bone’s resistance to twisting, was calculated for each slice
within the 1.2-mm defect region. The mean PMOI of the minimum
10% of slices was reported, as this is more indicative of the bone’s
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lack of union or propensity to fail. Specimens with no bone growth
for 11 consecutive slices possessed PMOI values of zero, but other
specimens that were visually nonunified may have possessed nonzero PMOI values.
After μCT imaging of the fracture calluses, the specimens were
moistened with PBS and frozen at –20°C until thawed for biomechanical testing as previously described (57). Briefly, specimens were potted
in polymethyl methacrylate (PMMA) bone cement (DePuyOrthopaedics Inc.) in square aluminum tube holders and allowed to rehydrate
in PBS at room temperature for 1 to 2 hours. Specimens were tested in
torsion using an EnduraTec TestBench system (200 N.mm torque cell;
Bose Corp.) at 1°/s until failure. The torque data were plotted against
the rotational deformation to determine the maximum torque, torsional rigidity, and energy to maximum.
Analysis of mouse tissue sections. From 5 to 7 specimens (tibia or
femur) in each group obtained at all time points were harvested,
fixed in 10% neutral buffered formalin for 3 days, decalcified in
14% EDTA (pH 7.2) for 10 to 14 days, paraffin processed, embedded, and sectioned at a thickness of 3 μm. Sections were stained
using ABH/OG staining and TRAP in order to analyze the cartilage
composition and osteoclast formation in the fracture callus tissues.
IHC stainings for COL3A1 (Abcam, ab7778) and RBPjκ (Cell Signaling) were performed on paraffin sections following the traditional
antigen retrieval and colorimetric development methodologies. Tissues prepared for frozen sections were fixed in 4% PFA for 2 hours at
4°C, decalcified with 14% EDTA at 4°C for 10 days, infiltrated with
gradient sucrose for 3 days, embedded with Tissue-Tek OCT medium, and sectioned at a thickness of 10 μm. LacZ staining and IF for
PECAM (BD Biosciences, 550274) were performed on frozen sections. Cartilage area, bone area, mesenchyme area, and OC.S./B.S.
were quantified on ABH/OG-stained and TRAP-stained sections
using the Visiopharm Integrator System (Visiopharm).
CFU and molecular assays. BMSCs were isolated from fractured
mice at 42 dpf or from WT mice at 2 months of age. Femurs and tibiae were removed and BM cells were flushed from the marrow cavity.
Cells were plated at a density of 1 × 106 cells/well in 6-well tissue culture plates for 14 days without change of mouse MSC medium (Stem
Cell Technologies). DAPT/DMSO-treated cultures were grown in
standard mouse MSC medium for 3 days and then supplemented
with DAPT (10 μM) or DMSO vehicle control for an additional 14
days. On either day 14 or 17 after plating, cells were fixed for crystal
violet and/or ALP staining. Type Ι colonies (CFU-F), as previously
described (15), and ALP-positive colonies (CFU-OB) were scored.
RNA was isolated using the RNeasy Mini Kit (QIAGEN) according to the manufacturer’s instructions. Real-time quantitative PCR
(qPCR) was performed to analyze relative gene expression using
the Bio-Rad CFX Connect Real-Time qPCR System. Gene expression was normalized to β-actin prior to being normalized to control
samples. Mouse primers for Hes1, Lepr, Col1a1, Alp, Oc, and β-actin
are listed in Supplemental Table 1.
Western blot. Bone proteins were extracted from femora and tibiae of Prx1-Cre RBPjkfl/fl, Col1a1-Cre; RBPjkfl/fl, and control mice with
RIPA buffer supplemented with protease inhibitors and phosphatase
inhibitors (Thermo Scientific, 78440) after BM cells were flushed
away. Proteins were fractionated in an SDS-PAGE gel, transferred
to a nitrocellulose membrane, and detected with the RBPjκ antibody
(Cell Signaling, 5313).
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Statistics. All results are presented as the mean ± SD. Comparisons
between 2 groups were analyzed using 2-tailed, unpaired Student’s
t test. Two-way ANOVA followed by Dunnett’s post hoc test was used
for comparison of 2 groups at multiple time points. P < 0.05 was considered statistically significant.
Study approval. All animal studies were approved by the University of Rochester Committee on Animal Resources and the Duke University Institutional Animal Use and Care Committee.
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